These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 19673650)

  • 21. Virological escape in HCV genotype-1-infected patients receiving daclatasvir plus ribavirin and peginterferon alfa-2a or alfa-2b.
    McPhee F; Hernandez D; Zhou N; Yu F; Ueland J; Monikowski A; Chayama K; Toyota J; Izumi N; Yokosuka O; Kawada N; Osaki Y; Hughes EA; Watanabe H; Ishikawa H; Kumada H
    Antivir Ther; 2014; 19(5):479-90. PubMed ID: 24448487
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of retreatment with interferon alone or interferon plus ribavirin on hepatitis C virus quasispecies diversification in nonresponder patients with chronic hepatitis C.
    Gerotto M; Sullivan DG; Polyak SJ; Chemello L; Cavalletto L; Pontisso P; Alberti A; Gretch DR
    J Virol; 1999 Sep; 73(9):7241-7. PubMed ID: 10438811
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Correlation between mutations in the core and NS5A genes of hepatitis C virus genotypes 1a, 1b, 3a, 3b, 6f and the response to pegylated interferon and ribavirin combination therapy.
    Kumthip K; Pantip C; Chusri P; Thongsawat S; O'Brien A; Nelson KE; Maneekarn N
    J Viral Hepat; 2011 Apr; 18(4):e117-25. PubMed ID: 20955493
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevalence of hepatitis C virus genotype 1a in Japan and correlation of mutations in the NS5A region and single-nucleotide polymorphism of interleukin-28B with the response to combination therapy with pegylated-interferon-alpha 2b and ribavirin.
    Hayashi K; Katano Y; Kuzuya T; Tachi Y; Honda T; Ishigami M; Itoh A; Hirooka Y; Ishikawa T; Nakano I; Urano F; Yoshioka K; Toyoda H; Kumada T; Goto H
    J Med Virol; 2012 Mar; 84(3):438-44. PubMed ID: 22246829
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapy.
    El-Shamy A; Nagano-Fujii M; Sasase N; Imoto S; Kim SR; Hotta H
    Hepatology; 2008 Jul; 48(1):38-47. PubMed ID: 18537193
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pegylated interferon-α monotherapy leads to low response rates in HIV-infected patients with acute hepatitis C.
    Arends JE; van Assen S; Stek CJ; Wensing AM; Fransen JH; Schellens IM; Spijkers SN; Mudrikova T; van Baarle D; Sprenger HG; Hoepelman AI
    Antivir Ther; 2011; 16(7):979-88. PubMed ID: 22024513
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetic heterogeneity of hepatitis C virus (HCV) in clinical strains of HIV positive and HIV negative patients chronically infected with HCV genotype 3a.
    Bagaglio S; Bruno R; Lodrini S; De Mitri MS; Andreone P; Loggi E; Galli L; Lazzarin A; Morsica G
    J Biol Regul Homeost Agents; 2003; 17(2):153-61. PubMed ID: 14518715
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of sequences of hepatitis C virus NS5A genotype 1 in HIV-coinfected patients with a null response to nitazoxanide or peg-interferon plus ribavirin.
    Sede M; Laufer N; Ojeda D; Gun A; Cahn P; Quarleri J
    Arch Virol; 2013 Sep; 158(9):1907-15. PubMed ID: 23553458
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
    Martin-Carbonero L; Nuñez M; Mariño A; Alcocer F; Bonet L; García-Samaniego J; López-Serrano P; Cordero M; Portu J; Soriano V
    AIDS; 2008 Jan; 22(1):15-21. PubMed ID: 18090387
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors.
    Yamada G; Iino S; Okuno T; Omata M; Kiyosawa K; Kumada H; Hayashi N; Sakai T
    Clin Drug Investig; 2008; 28(1):9-16. PubMed ID: 18081356
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients.
    Dominguez S; Ghosn J; Valantin MA; Schruniger A; Simon A; Bonnard P; Caumes E; Pialoux G; Benhamou Y; Thibault V; Katlama C
    AIDS; 2006 May; 20(8):1157-61. PubMed ID: 16691067
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial.
    Manns M; Reesink H; Berg T; Dusheiko G; Flisiak R; Marcellin P; Moreno C; Lenz O; Meyvisch P; Peeters M; Sekar V; Simmen K; Verloes R
    Antivir Ther; 2011; 16(7):1021-33. PubMed ID: 22024518
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of Hepatitis C Virus Genotype 1b Core and NS5A Mutations on Response to Peginterferon Plus Ribavirin Combination Therapy.
    Nakamoto S; Imazeki F; Arai M; Yasui S; Nakamura M; Haga Y; Sasaki R; Kanda T; Shirasawa H; Yokosuka O
    Int J Mol Sci; 2015 Sep; 16(9):21177-90. PubMed ID: 26370958
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quasispecies heterogeneity within the E1/E2 region as a pretreatment variable during pegylated interferon therapy of chronic hepatitis C virus infection.
    Chambers TJ; Fan X; Droll DA; Hembrador E; Slater T; Nickells MW; Dustin LB; Dibisceglie AM
    J Virol; 2005 Mar; 79(5):3071-83. PubMed ID: 15709027
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of ribavirin monotherapy on the viral population in patients with chronic hepatitis C genotype 1: direct sequencing and pyrosequencing of the HCV regions.
    Quiles-Pérez R; Muñoz-de-Rueda P; Maldonado AM; Martín-Álvarez A; Quer J; Salmerón J
    J Med Virol; 2014 Nov; 86(11):1886-97. PubMed ID: 25091333
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differences in virological response to pegylated interferon and ribavirin between hepatitis C virus (HCV)-monoinfected and HCV-HIV-coinfected patients.
    Tural C; Galeras JA; Planas R; Coll S; Sirera G; Giménez D; Salas A; Rey-Joly C; Cirera I; Márquez C; Tor J; Videla S; García-Retortillo M; Clotet B; Solà R
    Antivir Ther; 2008; 13(8):1047-55. PubMed ID: 19195330
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Amino acid substitutions in the hepatitis C virus core region of genotype 1b affect very early viral dynamics during treatment with telaprevir, peginterferon, and ribavirin.
    Akuta N; Suzuki F; Hirakawa M; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2010 Apr; 82(4):575-82. PubMed ID: 20166188
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patients.
    Pineda JA; Mira JA; Gil Ide L; Valera-Bestard B; Rivero A; Merino D; Girón-González JA; Ríos-Villegas MJ; González-Serrano M; Collado A; García-García JA; Carrillo-Gómez R; López-Cortés LF; Gómez-Mateos J
    J Antimicrob Chemother; 2007 Dec; 60(6):1347-54. PubMed ID: 17938129
    [TBL] [Abstract][Full Text] [Related]  

  • 39. OPERA: use of pegylated interferon plus ribavirin for treating HCV-HIV coinfection in interferon-naive patients.
    Carosi G; Bruno R; Cariti G; Nasta P; Gulminetti R; Galli M; Angarano G; Verucchi G; Pontali E; Capetti A; Raise E; Ravasio V; Maida I; Iannacone C; Caputo A; Puoti M
    Antivir Ther; 2014; 19(8):735-45. PubMed ID: 24583976
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Significance of a reduction in HCV RNA levels at 4 and 12 weeks in patients infected with HCV genotype 1b for the prediction of the outcome of combination therapy with peginterferon and ribavirin.
    Toyoda H; Kumada T; Shimada N; Takaguchi K; Ide T; Sata M; Ginba H; Matsuyama K; Izumi N
    BMC Infect Dis; 2012 Nov; 12():324. PubMed ID: 23181537
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.